{"entity":{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","aka":[],"tldr":"ONK Therapeutics, based in Galway, Ireland, is developing off-the-shelf natural killer cell therapies that are gene-edited and given two ways to kill cancer cells at once. It is a private, preclinical-stage company spun out of University of Galway research.","summary":"ONK Therapeutics is a privately held Irish company founded in 2015 on the NK cell and apoptosis research of Prof Michael O'Dwyer and collaborators at the University of Galway. It is developing next-generation off-the-shelf, optimally engineered natural killer (NK) cell therapies for haematological malignancies and solid tumours. Its platform combines a chimeric antigen receptor against a tumour antigen with a TRAIL variant that engages the death receptor pathway (DR4 or DR5), a dual-targeted design intended to improve efficacy and reduce antigen escape; the company also holds a European patent on CISH knockout in NK cells. In December 2023 ONK announced a research partnership with NAYA Biosciences to combine its NK cells with FLEX-NK bispecific antibodies. No clinical trial or financing round was described on the fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.onktherapeutics.com/"},{"label":"About ONK","url":"https://www.onktherapeutics.com/about/"},{"label":"News","url":"https://www.onktherapeutics.com/news/"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced (company is private and Irish, no SEC filings). Most recent news item on the site is dated December 2023, so current activity level is uncertain."],"hq":"Galway","country":"IE","companyType":"cell-therapy","website":"https://www.onktherapeutics.com/","founded":2015,"stage":"startup","investors":[],"funding":[]},"route":"/companies/onk-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}]}}